Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fusen Pharmaceutical Company Limited has announced that its subsidiary, Jiaheng Pharmaceutical Technology, has submitted an application for its new hypertension treatment, Measartan Potassium Tablets, which has been accepted by the National Medical Products Administration of the PRC. The medication, which comes in two dosages, offers a promising treatment for adults with primary hypertension and is poised to strengthen the company’s product line in the circulatory system market. As a Category B medicine under the National Medical Insurance in China, it is expected to be a first-line treatment with significant benefits and comparable safety to reference preparations.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.